Drug Discovery Pipeline
Highly Valuable Markets

C4X Discovery is using its unique proprietary technologies to build a pipeline of high quality small molecule drug candidates addressing valuable markets with high unmet medical need.

C4XD-pipeline

At present, C4X Discovery’s portfolio targets addiction, diabetes, inflammatory diseases (COPD and psoriasis) and oncology and includes small molecule versions of marketed biologics.

The Company's first drug candidate is an oral Orexin-1 antagonist for the treatment of addiction, with its primary indication as an aid to smoking cessation. It is currently in pre-clinical development with a regulatory submission to conduct a Phase I clinical trial planned for late 2016. C4X Discovery is currently expanding its pipeline and expects to ultimately initiate more than 4 therapeutic projects each year at steady state. C4XD now has five therapeutic projects underway.

ADDICTION

Hot GPCR targets lacking target protein crystal structure at project initiation

OREXIN-1 ANTAGONIST
($13bn)1

Read More

Diabetes

Hot GPCR targets lacking target protein crystal structure at project initiation

GPR142 AGONIST
($55bn)3

Marketed Biologics (clinically validated) with small molecule opportunity

GLP-1 AGONIST
($55bn)3

Read More

Inflammation

Intracellular target protein structure available, less tractable to conventional screening but enabled by C4X

NRF-2, COPD
($41bn)2

Marketed Biologics (clinically validated) with small molecule opportunity

ANTI-IL-17, PSORIASIS
($9bn)4

Read More

Oncology

Intracellular target protein structure available, less tractable to conventional screening but enabled by C4X

SGC COLLABORATION
(Inititated Nov 15)

Read More
  1. Market size in 2018; Source: GBI Research 2012
  2. Market size in 2017; Source: Visiongain, Asthma and COPD Therapies: World Market 2013-2023
  3. Market size in 2017; Source: Visiongain, Diabetes-Treatments-World-Drug-Market-2013-2023
  4. Market size in 2018; Source Visiongain, Psoriasis Treatment; Decision Resources
c4xd pipeline hot gpcr g

Hot GPCR targets lacking target protein crystal structure at project initiation

c4xd pipeline biologicals g

Marketed Biologics (clinically validated) with small molecule opportunity

c4xd pipeline intracellular g

Intracellular target protein structure available, novel hit finding less successful with conventional screening but enabled by C4X